[1]
|
Osuchowski, M., Johnson, V., He, Q. and Sharma, R. (2004) Alterations in Regional Brain Neurotransmitters by Silymarin, a Natural Antioxidant Flavonoid Mixture, in BALB/c Mice. Pharmaceutical Biology, 42, 384-389.
http://dx.doi.org/10.1080/13880200490519712
|
[2]
|
Kroll, D.J., Shaw, H.S. and Oberlies, N.H. (2007) Milk Thistle Nomenclature: Why It Matters in Cancer Research and Pharmacokinetic Studies. Integrative Cancer Therapies, 6, 110-119. http://dx.doi.org/10.1177/1534735407301825
|
[3]
|
Davis-Searles, P.R., et al. (2005) Milk Thistle and Prostate Cancer: Differential Effects of Pure Flavonolignans from Silybum marianum on Antiproliferative end Points in Human Prostate Carcinoma Cells. Cancer Research, 65, 4448-4457. http://dx.doi.org/10.1158/0008-5472.CAN-04-4662
|
[4]
|
Kiruthiga, P.V., Beema Shafreen, R., Karutha Pandian, S. and Pandima Devi, K. (2007) Silymarin Protection against Major Reactive Oxygen Species Released by Environmental Toxins: Exogenous H2O2 Exposure in Erythrocytes. Basic Clinical Pharmacology Toxicology, 100, 414-419. http://dx.doi.org/10.1111/j.1742-7843.2007.00069.x
|
[5]
|
Manna, S.K., Mukhopadhyay, A., Van, N.T. and Aggarwal, B.B. (1999) Silymarin Suppresses TNF-Induced Activation of NF-Kappa B, c-Jun N-terminal Kinase, and Apoptosis. Journal of Immunology, 163, 6800-6809.
|
[6]
|
Li, L.H., et al. (2007) Silymarin Enhanced Cytotoxic Effect of Anti-Fas Agonistic Antibody CH11 on A375-S2 Cells. Journal of Asian Natural Products Research, 9, 593-602. http://dx.doi.org/10.1080/10286020600882502
|
[7]
|
Singh, R.P. and Agarwal, R. (2006) Prostate Cancer Chemoprevention by Silibinin: Bench to Bedside. Molecular Carcinogenesis, 45, 436-442. http://dx.doi.org/10.1002/mc.20223
|
[8]
|
Singh, R.P. and Agarwal, R. (2004) A Cancer Chemopreventive Agent Silibinin, Targets Mitogenic and Survival Signaling in Prostate Cancer. Mutation Research, 555, 21-32. http://dx.doi.org/10.1016/j.mrfmmm.2004.05.017
|
[9]
|
Zi, X., Grasso, A.W., Kung, H.J. and Agarwal, R. (1998) A Flavonoid Antioxidant, Silymarin, Inhibits Activation of erbB1 Signaling and Induces Cyclin-Dependent Kinase Inhibitors, G1 Arrest, and Anticarcinogenic Effects in Human Prostate Carcinoma DU145 Cells. Cancer Research, 58, 1920-1929.
|
[10]
|
Scambia, G., et al. (1996) Antiproliferative Effect of Silybin on Gynaecological Malignancies: Synergism with Cisplatin and Doxorubicin. European Journal of Cancer, 32A, 877-882. http://dx.doi.org/10.1016/0959-8049(96)00011-1
|
[11]
|
Sharma, G., Singh, R.P., Chan, D.C. and Agarwal, R. (2003) Silibinin Induces Growth Inhibition and Apoptotic Cell Death in Human Lung Carcinoma Cells. Anticancer Research, 23, 2649-2655.
|
[12]
|
Zi, X., Feyes, D.K. and Agarwal, R. (1998) Anticarcinogenic Effect of a Flavonoid Antioxidant, Silymarin, in Human Breast Cancer Cells MDA-MB 468: Induction of G1 Arrest through an Increase in Cip1/p21 Concomitant with a Decrease in Kinase Activity of Cyclin-Dependent Kinases and Associated Cyclins. Clinical Cancer Research, 4, 1055-1064.
|
[13]
|
Deep, G., Oberlies, N.H., Kroll, D.J. and Agarwal, R. (2007) Isosilybin B and Isosilybin A Inhibit Growth, Induce G1 Arrest and Cause Apoptosis in Human Prostate Cancer LNCaP and 22Rv1 Cells. Carcinogenesis, 28, 1533-1542.
http://dx.doi.org/10.1093/carcin/bgm069
|
[14]
|
Roy, S., Kaur, M., Agarwal, C., Tecklenburg, M., Sclafani, R.A. and Agarwal, R. (2007) p21 and p27 Induction by Silibinin Is Essential for Its Cell Cycle Arrest Effect in Prostate Carcinoma Cells. Molecular Cancer Therapeutics, 6, 2696-2707.
|
[15]
|
Kaur, M., et al. (2009) Silibinin Suppresses Growth and Induces Apoptotic Death of Human Colorectal Carcinoma LoVo Cells in culture and Tumor Xenograft. Molecular Cancer Therapeutics, 8, 2366-2374.
http://dx.doi.org/10.1158/1535-7163.MCT-09-0304
|
[16]
|
Zhu, W., Zhang, J.S. and Young, C.Y. (2001) Silymarin Inhibits Function of the Androgen Receptor by Reducing Nuclear Localization of the Receptor in the Human Prostate Cancer Cell Line LNCaP. Carcinogenesis, 22, 1399-1403.
http://dx.doi.org/10.1093/carcin/22.9.1399
|
[17]
|
Jemal, A., et al. (2011) Global Cancer Statistics. CA: A Cancer Journal for Clinicians, 61, 69-90.
http://dx.doi.org/10.3322/caac.20107
|
[18]
|
Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D. and Bray, F. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. http://globocan.iarc.fr
|
[19]
|
Mousavi, S.M., et al. (2007) Breast Cancer in Iran: An Epidemiological Review. The Breast Journal, 13, 383-391.
http://dx.doi.org/10.1111/j.1524-4741.2007.00446.x
|
[20]
|
Noroozi, A., Jomand, T. and Tahmasebi, R. (2011) Determinants of Breast Self-Examination Performance among Iranian Women: An Application of the Health Belief Model. Journal of Cancer Education, 26, 365-374.
http://dx.doi.org/10.1007/s13187-010-0158-y
|
[21]
|
Bidgoli, S.A., Ahmadi, R. and Zavarhei, M.D. (2010) Role of Hormonal and Environmental Factors on Early Incidence of Breast Cancer in Iran. Science of the Total Environment, 408, 4056-4061.
http://dx.doi.org/10.1016/j.scitotenv.2010.05.018
|
[22]
|
Deep, G. and Agarwal, R. (2007) Chemopreventive Efficacy of Silymarin in Skin and Prostate Cancer. Integrative Cancer Therapies, 6, 130-145. http://dx.doi.org/10.1177/1534735407301441
|
[23]
|
Gharagozloo, M. and Amirghofran, Z. (2007) Effects of Silymarin on the Spontaneous Proliferation and Cell Cycle of Human Peripheral Blood Leukemia T Cells. Journal of Cancer Research and Clinical Oncology, 133, 525-532.
http://dx.doi.org/10.1007/s00432-007-0197-x
|
[24]
|
Singh, R.P., et al. (2005) Silibinin Strongly Inhibits Growth and Survival of Human Endothelial Cells via Cell Cycle Arrest and Downregulation of Survivin, Akt and NF-kappaB: Implications for Angioprevention and Antiangiogenic Therapy. Oncogene, 24, 1188-1202. http://dx.doi.org/10.1038/sj.onc.1208276
|
[25]
|
Li, W., et al. (2011) Molecular Mechanism of Silymarin-Induced Apoptosis in a Highly Metastatic Lung Cancer Cell Line Anip973. Cancer Biotherapy and Radiopharmaceuticals, 26, 317-324. http://dx.doi.org/10.1089/cbr.2010.0892
|
[26]
|
Gu, M., Singh, R.P., Dhanalakshmi, S., Agarwal, C. and Agarwal, R. (2007) Silibinin Inhibits Inflammatory and Angiogenic Attributes in Photocarcinogenesis in SKH-1 Hairless Mice. Cancer Research, 67, 3483-3491.
http://dx.doi.org/10.1158/0008-5472.CAN-06-3955
|
[27]
|
Rajamanickam, S., Velmurugan, B., Kaur, M., Singh, R.P. and Agarwal, R. (2010) Chemoprevention of Intestinal Tumorigenesis in APCmin/+ Mice by Silibinin. Cancer Research, 70, 2368-2378.
http://dx.doi.org/10.1158/0008-5472.CAN-09-3249
|
[28]
|
Kim, S., et al. (2011) Silibinin Suppresses EGFR Ligand-Induced CD44 Expression through Inhibition of EGFR Activity in Breast Cancer Cells. Anticancer Research, 31, 3767-3773.
|
[29]
|
Provinciali, M., et al. (2007) Effect of the Silybin-Phosphatidylcholine Complex (IdB 1016) on the Development of Mammary Tumors in HER-2/Neu Transgenic Mice. Cancer Research, 67, 2022-2029.
http://dx.doi.org/10.1158/0008-5472.CAN-06-2601
|